Meftal%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520spas

# Meftal spas ## Overview Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antimuscarinic agent. Mefenamic acid reduces inflammation and pain. Hyoscine butylbromide reduces smooth muscle spasms in the gastrointestinal tract. ## Primary Indications * Symptomatic relief of spasmodic abdominal pain. * Painful menstruation (dysmenorrhea). ## Adult Dosing * **Mefenamic acid:** 500 mg every 8 hours. Dosing should not exceed 7 days. * **Hyoscine butylbromide:** Typically 10 mg every 8 hours. * Specific dosing may vary based on local protocol and patient response. ## Pediatric Dosing Mefenamic acid is generally not recommended for children under 12 years of age. Hyoscine butylbromide pediatric dosing is not well-established and should be determined by a pediatrician. ## Dose Adjustments No specific dose adjustments are typically outlined for renal or hepatic impairment in standard prescribing information for this combination product. However, caution is advised in patients with pre-existing renal or hepatic disease. ## Contraindications * Hypersensitivity to mefenamic acid, hyoscine butylbromide, or any component of the formulation. * Active gastrointestinal bleeding or perforation. * History of gastrointestinal ulceration or bleeding. * Severe renal or hepatic impairment. * Myasthenia gravis. * Tachycardia. * Prostatic hypertrophy with urinary retention. * Glaucoma. * Ileus or obstructive gastrointestinal disorders. * Pyloric stenosis. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, constipation, dizziness, headache. * **Less Common/Serious:** Gastrointestinal bleeding/ulceration, renal impairment, hepatic impairment, hypersensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, blurred vision, dry mouth, urinary retention, tachycardia. ## Key Drug Interactions * **NSAIDs (e.g., mefenamic acid) with:** * Anticoagulants (e.g., warfarin): Increased risk of bleeding. * Corticosteroids: Increased risk of gastrointestinal ulceration and bleeding. * SSRIs/SNRIs: Increased risk of gastrointestinal bleeding. * Lithium: Increased lithium levels. * Methotrexate: Increased methotrexate toxicity. * Diuretics and antihypertensives: May reduce efficacy and increase risk of renal impairment. * **Antimuscarinics (e.g., hyoscine butylbromide) with:** * Other anticholinergic agents: Additive effects, increased risk of side effects. * Amantadine: Increased anticholinergic effects. * Tricyclic antidepressants: Increased anticholinergic effects. ## Monitoring * Monitor for signs and symptoms of gastrointestinal bleeding (e.g., melena, hematemesis). * Monitor renal and hepatic function, especially with prolonged use or in patients with pre-existing conditions. * Assess for signs of hypersensitivity reactions. * Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention). ## Clinical Pearls * Use the lowest effective dose for the shortest duration necessary. * Administer with food or milk to reduce gastrointestinal upset. * Avoid concurrent use with other NSAIDs or salicylates. * Discontinue use if severe adverse effects occur. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines for complete details and to verify dosages and recommendations.*